Mouse Anti-IRAK4 Recombinant Antibody (CBWJN-1113) (CBMAB-N0882-WJ)

Name: Mouse Anti-IRAK4 Recombinant Antibody (CBWJN-1113)
SKU: CBMAB-N0882-WJ
Rating: 5 (1 reviews)

See all IRAK4 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBWJN-1113

Application

WB, ICC, IHC-P, IHC-F, ELISA

Specificity

Human

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, pH 7.4, 50% glycerol

Preservative

0.02% sodium azide

Concentration

0.5 mg/mL

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

interleukin-1 receptor-associated kinase 4

Introduction

This gene encodes a kinase that activates NF-kappaB in both the Toll-like receptor (TLR) and T-cell receptor (TCR) signaling pathways. The protein is essential for most innate immune responses. Mutations in this gene result in IRAK4 deficiency and recurrent invasive pneumococcal disease. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2011]

Entrez Gene ID

51135

UniProt ID

Q9NWZ3

Alternative Names

Interleukin 1 Receptor Associated Kinase 4

Function

Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways (PubMed:17878374).
Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation to form the Myddosome together with IRAK2. Phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation suggesting a similar mechanism during microbial infections.

Biological Process

Cytokine-mediated signaling pathwayManual Assertion Based On ExperimentIBA:GO_Central
Innate immune responseManual Assertion Based On ExperimentTAS:UniProtKB
Interleukin-1-mediated signaling pathwayTAS:Reactome
Intracellular signal transductionManual Assertion Based On ExperimentIBA:GO_Central
JNK cascadeIEA:Ensembl
MyD88-dependent toll-like receptor signaling pathwayManual Assertion Based On ExperimentTAS:UniProtKB
Neutrophil mediated immunityManual Assertion Based On ExperimentIMP:UniProtKB
Neutrophil migrationManual Assertion Based On ExperimentIMP:UniProtKB
Positive regulation of I-kappaB kinase/NF-kappaB signalingManual Assertion Based On ExperimentIMP:MGI
Positive regulation of smooth muscle cell proliferationIEA:Ensembl
Toll-like receptor 9 signaling pathwayTAS:Reactome
Toll-like receptor signaling pathwayManual Assertion Based On ExperimentTAS:UniProtKB

Cellular Location

Cytoplasm

Involvement in disease

Immunodeficiency 67 (IMD67):
An autosomal recessive primary immunodeficiency characterized by recurrent, life-threatening systemic and invasive bacterial infections beginning in infancy or early childhood.

PTM

Phosphorylated.

Lavazais, S., Jargosch, M., Dupont, S., Labéguère, F., Menet, C., Jagerschmidt, C., ... & Brys, R. (2023). IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases. Science Translational Medicine, 15(683), eabj3289.

Bennett, J., & Starczynowski, D. T. (2022). IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Current Opinion in Hematology, 29(1), 8.

Pereira, M., Durso, D. F., Bryant, C. E., Kurt-Jones, E. A., Silverman, N., Golenbock, D. T., & Gazzinelli, R. T. (2022). The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways. Cell reports, 40(7).

Umar, S., Palasiewicz, K., Van Raemdonck, K., Volin, M. V., Romay, B., Amin, M. A., ... & Shahrara, S. (2021). IRAK4 inhibition: a promising strategy for treating RA joint inflammation and bone erosion. Cellular & Molecular Immunology, 18(9), 2199-2210.

Zhang, J., Fu, L., Shen, B., Liu, Y., Wang, W., Cai, X., ... & Dai, X. (2020). Assessing IRAK4 functions in ABC DLBCL by IRAK4 kinase inhibition and protein degradation. Cell Chemical Biology, 27(12), 1500-1509.

Wang, H., Zhou, H., Zhang, Q., Poulsen, K. L., Taylor, V., McMullen, M. R., ... & Li, X. (2020). Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice. Journal of hepatology, 73(6), 1470-1481.

Nunes, J., McGonagle, G. A., Eden, J., Kiritharan, G., Touzet, M., Lewell, X., ... & Anderson, N. A. (2019). Targeting IRAK4 for degradation with PROTACs. ACS medicinal chemistry letters, 10(7), 1081-1085.

Smith, M. A., Choudhary, G. S., Pellagatti, A., Choi, K., Bolanos, L. C., Bhagat, T. D., ... & Starczynowski, D. T. (2019). U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature cell biology, 21(5), 640-650.

Bryan, M. C., Drobnick, J., Gobbi, A., Kolesnikov, A., Chen, Y., Rajapaksa, N., ... & Kiefer, J. R. (2019). Development of potent and selective pyrazolopyrimidine IRAK4 inhibitors. Journal of Medicinal Chemistry, 62(13), 6223-6240.

Hjorton, K., Hagberg, N., Israelsson, E., Jinton, L., Berggren, O., Sandling, J. K., ... & Rönnblom, L. (2018). Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. Arthritis research & therapy, 20, 1-11.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-IRAK4 Recombinant Antibody (CBWJN-1113)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-IRAK4 Recombinant Antibody (CBT786) (CAT#: V2LY-0625-LY3277)

Mouse Anti-IRAK4 Recombinant Antibody (2C7) (CAT#: CBMAB-A4527-LY)

Mouse Anti-IRAK4 Recombinant Antibody (1D4) (CAT#: CBMAB-A4525-LY)

Mouse Anti-IRAK4 Recombinant Antibody (2H9-F11) (CAT#: CBMAB-Z0362-LY)

Mouse Anti-IRAK4 Recombinant Antibody (CBYY-I0711) (CAT#: CBMAB-I1580-YY)

Human Anti-IRAK4 Recombinant Antibody (CBYY-I0417) (CAT#: CBMAB-I1015-YY)

Mouse Anti-IRAK4 Recombinant Antibody (CBT4351) (CAT#: V2LY-0625-LY2681)

Mouse Anti-IRAK4 Recombinant Antibody (4E8) (CAT#: CBMAB-A4522-LY)

Mouse Anti-IRAK4 Recombinant Antibody (CBYY-I0751) (CAT#: CBMAB-I1665-YY)

Mouse Anti-IRAK4 Recombinant Antibody (CBYY-I1493) (CAT#: CBMAB-I2663-YY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry